Loading clinical trials...

Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia | Clinical Trials | Clareo Health

COMPLETED

Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia

NCT05642533•Novo Nordisk A/S

Summary

The purpose of this research study is to collect information on participants body weight, blood sugar levels, heart related diseases and lifestyle. The collected information will help estimate the prevalence of participants disease. This study will take about 6 months. However, participants involvement in the study will not extend beyond their routine visit and will thus require a maximum of 1 day. If participants choose to take part, they will be asked to give information about their health in routine clinical visit. Participants will be asked to complete a questionnaire about their lifestyle. Participants will complete this questionnaire during their normally scheduled visit with their doctor. Participants will continue their normal way of life and will not get any medication other than those prescribed to them by their doctor. Participants will have no direct benefit from participation in this study and there are no risks involved. Participants decide voluntarily whether they want to participate in this study or not. Participants' decision will not affect their medical care and they do not have to justify their decision. Participants are free to leave the study at any time and without giving reasons. This does not affect their current or future treatment. The data collected up to that point are still being evaluated. There is no additional cost to participants for being in this study.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed consent obtained before any study related activities (study related activities are any procedure-related to recording of data according to the protocol).
•2. Diagnosed with obesity (BMI higher than or equal to 30 for all ethnic groups except Asian; BMI higher than or equal to 27.5 for patients of Asian ethnicity).
•3. Diagnosed with T2D for patients in Cohort 2.
•4. Male or female, aged between 18 and 75 years at the time of signing informed consent

Exclusion Criteria

•1. Participation in an interventional clinical trial during the study period.
•2. Diagnosed with T2D for patients in Cohort 1.
•3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Key Dates

Start Date

December 31, 2022

Primary Completion Date

September 14, 2023

Completion Date

September 14, 2023

Last Updated

December 30, 2025

Enrollment

1,061

ACTUAL participants

Conditions

Obesity and Cardiovascular Risk

Interventions

No treatment given

OTHER

Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

NCT07297290

Obesity and Cardiovascular RiskInsulin Resistance+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions